Kolexia
Debarri Houria Hématologie
Debarri Houria
Hématologie
Hôpital Mercy
Ars-Laquenexy, France
46 Activités
76 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Myélome multiple Maladie résiduelle Leucémie prolymphocytaire à cellules T Macroglobulinémie de Waldenström Récidive tumorale locale Maladie aigüe

Collaborateurs

Voir plus
Dorvaux Veronique
Dorvaux Veronique
Hôpital Mercy, Ars-Laquenexy, France
Carassou Philippe
Carassou Philippe
Hia Legouest, Metz, France
Leleu Xavier
Leleu Xavier
Hôpital La Miletrie, Poitiers, France
Meunier Godelieve
Meunier Godelieve
Hôpital Mercy, Ars-Laquenexy, France

Industries

Voir plus
Janssen
7 collaboration(s)
Dernière en 2023
Amgen
3 collaboration(s)
Dernière en 2023
Novartis
2 collaboration(s)
Dernière en 2023
Pfizer
2 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
ALFA2101: An ALFA 2101 Multicenter Randomized Phase II Study: CPX-351 Versus Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
Essai Clinique (CHU Nice)   29 janvier 2024
Efficacy and Safety of Luspatercept +/- Erythropoiesis-Stimulating Agent (ESA) in Patients with Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS): A French Multicenter Prospective Real-Life Registry
65th ASH Annual Meeting Abstracts   02 novembre 2023
LAMSA2020: A Phase II Randomized Study to Assess the Efficacy on Outcome of Venetoclax Combined With Cytarabine Versus Idarubicin Combined With Cytarabine Administered as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission
Essai Clinique (French Innovative Leukemia Organisation)   07 septembre 2023
Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
Annual Meeting Abstracts 2022   15 novembre 2022
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.
Leukemia   14 novembre 2022
Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab
Blood   23 novembre 2021
Discontinuation of antimicrobial therapy in adult neutropenic haematology patients: A prospective cohort.
International journal of antimicrobial agents   02 mars 2019
French Registry of First-line Treatment of Acute Promyelocytic Leukemia: The French Registry on the First-line Treatment of Non High-risk Acute Promyelocytic Leukemia (APL) in Patients Aged ≤ 70 Years
Essai Clinique (Teva)   17 octobre 2016
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
Oncotarget   27 septembre 2016
IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia.
Clinical cancer research : an official journal of the American Association for Cancer Research   11 mai 2016